Scholarlink

Introduction <p>Statin therapy up-titration is hindered in heart-transplant (HT) recipients due to concern for pharmacological interactions and side effects. Alternative lipid lowering therapies (LLT) are now available for patients who are poorly tolerant to statins or those with significant dyslipidaemia despite maximal dose statin treatment and dietary advice. Real-world studies with non-statin LLT are limited in HT population.</p> Aim <p>To examine the lipid status of HT patients following the increased adoption of non-statin lipid lowering therapies.</p> Methods <p>Single centre retrospective observational cohort study including adult HT patients under follow-up in a tertiary centre. From August 2024 to March 2025, 238 patients had lipid profile, prevalence of statin and non-statin LLT prescription assessed and compared to the same data measured in 2019/2020.</p> Results <p>Patients had a median age of 64 (IQR=53.3–72.0) years, 27% were female. Median LDL-C levels for paired values significantly decreased from 109.6 [88.9–133.0] to 93.8 [72.5–112.0] at last follow up (<i>p</i>&lt;0.001). The proportion of patients receiving ezetimibe sharply increased [73 (30.7%) compared to 27 (11.3%), <i>p</i>&lt;0.001]; 10 patients (4.2%) were receiving proprotein convertase subtilisin/kexin type 9 inhibitor&#xa0;monoclonal antibodies (PCSK9i), 3 (1.3%) inclisiran, 3 (1.3%) bempedoic acid, which were not commercially available at the time of the previous assessment. Also, the proportion of patients receiving statins increased during follow-up [145 (60.9%) vs 128 (52.1%), <i>p</i>&lt;0.001], mainly because of high-intensity statin adoption.</p> Conclusion <p>In a real-world cohort of HT recipients, increased adoption of ezetimibe, PCSK9-targeting therapies and bempedoic acid combined with intensification of statin therapy safely and efficiently reduced LDL-C.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of Non-statin Lipid-Lowering Therapies Implementation and Statin Treatment Intensification on Lipid Status in Heart Transplant Recipients: A Single-Centre Retrospective Cohort Study

  • 期刊论文

  • 发表日期：

    2026年5月5日

查看全文
  • Daniela Bacich,
  • Enrico Giuseppe Italiano,
  • Marika Faggioli,
  • Laura Rizzo,
  • Nicola Pradegan,
  • Giuseppe Toscano,
  • Chiara Tessari,
  • Vincenzo Tarzia

摘要

Introduction

Statin therapy up-titration is hindered in heart-transplant (HT) recipients due to concern for pharmacological interactions and side effects. Alternative lipid lowering therapies (LLT) are now available for patients who are poorly tolerant to statins or those with significant dyslipidaemia despite maximal dose statin treatment and dietary advice. Real-world studies with non-statin LLT are limited in HT population.

Aim

To examine the lipid status of HT patients following the increased adoption of non-statin lipid lowering therapies.

Methods

Single centre retrospective observational cohort study including adult HT patients under follow-up in a tertiary centre. From August 2024 to March 2025, 238 patients had lipid profile, prevalence of statin and non-statin LLT prescription assessed and compared to the same data measured in 2019/2020.

Results

Patients had a median age of 64 (IQR=53.3–72.0) years, 27% were female. Median LDL-C levels for paired values significantly decreased from 109.6 [88.9–133.0] to 93.8 [72.5–112.0] at last follow up (p<0.001). The proportion of patients receiving ezetimibe sharply increased [73 (30.7%) compared to 27 (11.3%), p<0.001]; 10 patients (4.2%) were receiving proprotein convertase subtilisin/kexin type 9 inhibitor monoclonal antibodies (PCSK9i), 3 (1.3%) inclisiran, 3 (1.3%) bempedoic acid, which were not commercially available at the time of the previous assessment. Also, the proportion of patients receiving statins increased during follow-up [145 (60.9%) vs 128 (52.1%), p<0.001], mainly because of high-intensity statin adoption.

Conclusion

In a real-world cohort of HT recipients, increased adoption of ezetimibe, PCSK9-targeting therapies and bempedoic acid combined with intensification of statin therapy safely and efficiently reduced LDL-C.

Graphical Abstract